BBLG Stock Forecast: Bone Biologics Corp. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 37 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Bone Biologics Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (81): Analysts have, on balance, been raising their forecasts.
Momentum (3): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
BBLG stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on BBLG, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Apr 2023 | EF Hutton | Reiterates | Buy | $2.25 |
| 3 Apr 2023 | EF Hutton | Reiterates | Buy | $2.25 |
| 18 Oct 2022 | EF Hutton | Initiates | Buy | $2.25 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
BBLG appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
BBLG vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Bone Biologics Corp. returned −81.1% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
BBLG analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 0.2×
- EV / EBITDA
- —
Cheaper than 95% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −47.5%
- Return on assets
- −29.5%
- Dividend yield
- —
Higher than 22% of US stocks
Higher than 14% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Bone Biologics Corp. has a market value of $932K.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$2.9M.
Free cash flow in the twelve months to 30 June 2026: −$2.6M.
Bone Biologics Corp. employs 2 people.
Data provided by Twelve Data
BBLG and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at BBLG’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Bone Biologics Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about BBLG
How does Ticker Nerd's model rank BBLG?
As at 21 Nov 2026, Bone Biologics Corp. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (81 of 100).
What is the BBLG stock forecast for 2030?
No analyst covering Bone Biologics Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BBLG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $12 over the next 12 months.
How has BBLG stock performed over the past year?
Bone Biologics Corp. returned -81.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Bone Biologics Corp. do?
Bone Biologics Corp is a clinical-stage medical device company focused on orthobiologic products for spinal fusion and bone regeneration. The company’s current work centers on NELL-1, a recombinant human protein used with demineralized bone matrix to support targeted bone healing in lumbar spinal fusion procedures.
About Bone Biologics Corp.
Bone Biologics Corp is a clinical-stage medical device company focused on orthobiologic products for spinal fusion and bone regeneration. The company’s current work centers on NELL-1, a recombinant human protein used with demineralized bone matrix to support targeted bone healing in lumbar spinal fusion procedures. Its product development is aimed at improving outcomes in skeletal repair, with applications that extend across spinal, orthopedic, reconstructive, neurosurgical, and sports medicine settings. Bone Biologics Corp operates in the healthcare technology and medical specialties space, where orthobiologics play an important role in supporting bone growth and repair during surgery. Headquartered in Burlington, Massachusetts, Bone Biologics Corp is positioned as a developer of regenerative solutions for surgeons and medical centers working with complex bone-related procedures.
CEO Mr. Jeffrey Frelick · 2 employees · United States · https://www.bonebiologics.com